RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 882.20K | 852.90K | 707.50K | 845.90K | 997.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 882.20K | 852.90K | 707.50K | 845.90K | 997.20K |
| Cost of Revenue | 428.50K | 572.40K | 522.00K | 1.40M | 731.80K |
| Gross Profit | 453.70K | 280.60K | 185.60K | -550.30K | 265.50K |
| SG&A Expenses | 1.19M | 1.59M | 1.27M | 1.35M | 1.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.50K | 6.60K | 6.50K | -29.20K | 10.40K |
| Total Operating Expenses | 1.62M | 2.17M | 1.80M | 2.72M | 1.97M |
| Operating Income | -742.20K | -1.31M | -1.09M | -1.88M | -975.70K |
| Income Before Tax | -725.70K | -1.28M | -1.70M | -2.83M | -778.70K |
| Income Tax Expenses | -- | -- | -- | 7.10K | -- |
| Earnings from Continuing Operations | -725.70K | -1.28M | -1.70M | -2.84M | -778.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -725.70K | -1.28M | -1.70M | -2.84M | -778.70K |
| EBIT | -742.20K | -1.31M | -1.09M | -1.88M | -975.70K |
| EBITDA | -561.50K | -1.13M | -906.70K | -1.76M | -714.80K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.37M | 120.68M |
| Average Diluted Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.37M | 120.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
